Neoplasms, Nerve Tissue clinical trials at UC Health
2 research studies open to new patients

• Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers

  open to eligible people ages 1 month and up

  This is a Phase 1/2, multi-center, open-label study designed to evaluate the safety and efficacy of LOXO-195 when administered orally to patients age ≥ 1 month and older with NTRK fusion cancers treated with a prior TRK inhibitor.

  at UCLA

• Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)

  open to eligible people ages 12 years and up

  Phase II, multi-center, open-label study of patients with advanced solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3.

  at UCLA

Last updated: November 26, 2018